ovarian-cancer

Novel combination improves overall survival in platinum-resistant ovarian cancer—ROSELLA trial update.

Platinum-resistant ovarian cancer has a median OS of less than 12 months with standard chemotherapy and few effective options. The ROSELLA trial tested a novel regimen combining niraparib (PARP inhibitor) with dostarlimab (anti-PD-1 antibody) in platinum-resistant disease, and an updated analysis…

Novel combination improves overall survival in platinum-resistant ovarian cancer—ROSELLA trial update.

This represents meaningful clinical progress in a very poor-prognosis setting. The combination targets both homologous recombination deficiency (PARP inhibitor) and immune checkpoint (anti-PD-1), potentially creating synergistic anti-tumor effects.

The result supports this combination as a new treatment option for platinum-resistant ovarian cancer.

Key Findings

Niraparib + dostarlimab combination significantly improved OS in platinum-resistant ovarian cancer
ROSELLA trial update presented at SGO meeting
Significant OS improvement in a population with very limited options
Combination targets both DNA repair deficiency and immune checkpoint
Establishes a new treatment option for platinum-resistant disease

Implications

This combination could become a new standard of care option for platinum-resistant ovarian cancer. PARP inhibitor + checkpoint inhibitor combinations have rational biological synergy and this clinical validation is important. Biomarker analysis (HRD status, PD-L1) will be important for patient selection.

Caveats

Meeting abstract/news report with limited detail; abstract-only. Full data and subgroup analyses not available in this summary. Platinum-resistant disease is heterogeneous—patient selection for optimal benefit needs definition. Toxicity profile needs characterization.

Source: MedPage Hematology/Oncology — 2026-04-11

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.

Novel combination improves overall survival in platinum-resistant ovarian cancer—ROSELLA trial update.

Key Findings

Implications

Caveats

Read more

Landmark DCIS trial, CRC microbiome & AML combos

Colorectal Cancer Microbiome Discovery Platform

GBM Tumor Microenvironment Drug Target Atlas

BET Inhibitor Target Selectivity Database